R
Raghu Kalluri
Researcher at University of Texas MD Anderson Cancer Center
Publications - 325
Citations - 89851
Raghu Kalluri is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer & Angiogenesis. The author has an hindex of 115, co-authored 306 publications receiving 71127 citations. Previous affiliations of Raghu Kalluri include Beth Israel Deaconess Medical Center & Baylor College of Medicine.
Papers
More filters
Journal ArticleDOI
STOX1 deficiency is associated with renin-mediated gestational hypertension and placental defects
Jacqueline G. Parchem,Keizo Kanasaki,Soo Bong Lee,Megumi Kanasaki,Joyce L. Yang,Yong Xu,Kadeshia M. Earl,Rachel A. Keuls,Vincent H. Gattone,Raghu Kalluri +9 more
TL;DR: This study finds that gestational hypertension in Stox1-KO mice resulted from activation of the uteroplacental renin-angiotensin system, and demonstrates the utility of genetic mouse models for uncovering links between genetic variants and effector pathways implicated in the pathogenesis of hypertensive disorders of pregnancy.
Posted ContentDOI
Multiple antibodies identify glypican-1 associated with exosomes from pancreatic cancer cells and serum from patients with pancreatic cancer
Chengyan Dong,Li Huang,Sonia A. Melo,Paul Kurywchak,Qian Peng,Christoph Kahlert,Valerie S. LeBleu,Raghu Kalluri +7 more
TL;DR: Interestingly, the results highlight a specific enrichment of high molecular weight GPC1 on exosomes, potentially contributed by heparan sulfate and other glycosylation modifications.
Book ChapterDOI
Cardiac fibrosis: Cellular and molecular determinants
Hasse Brønnum,Raghu Kalluri +1 more
TL;DR: Cardiac fibrosis is an unavoidable consequence of chronic insult to the myocardium, characterized by wall stiffening, reduced contractility, and impaired overall heart performance.
Partial Epithelial-to- Mesenchymal Transition and Other New Mechanisms of
TL;DR: The cellular protagonists of this process includemyofibroblasts, tubular epithelial cells, endothelial cells and immune cells as mentioned in this paper, including partial epithelial-to-mes-enchymal transition (EMT), initiation and progression of kidney disease (CKD).
Journal ArticleDOI
Phase I study of mesenchymal stem cell (MSC)-derived exosomes with KRASG12D siRNA in patients with metastatic pancreatic cancer harboring a KRASG12D mutation.
Rishi Surana,Valerie S. LeBleu,J. Jack Lee,Brandon G. Smaglo,Dan-Dan Zhao,Michael S. Lee,Robert A. Wolfe,Michael J. Overman,Mayela Mendt,Kathleen M. McAndrews,Sujuan Yang,Katayoun Rezvani,Raghu Kalluri,Anirban Maitra,Elizabeth J. Shpall,Shubham Pant +15 more
TL;DR: The primary endpoints of this study are to determine a maximum tolerated dose (MTD) of KRASG12D-loaded exosomes and to identify dose-limiting toxicities (DLT).